drugset / Trial / NCT02466919
Study of Levofloxacin-based Concomitant Therapy for H. Pylori Eradication in Diabetic Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
The study aims to evaluate H. pylori eradication rate in diabetic patients by using novel 10-day levofloxacin-based concomitant therapy compared with conventional 10-day sequential therapy.
Timeline
- Start
- 2014-05
- Primary completion
- 2016-09
- Completion
- 2016-09
Publications
- Yang YJ, Wu CT, Ou HY, Lin CH, Cheng HC, Chang WL, Chen WY, Yang HB, Lu CC, Sheu BS. Male non-insulin users with type 2 diabetes mellitus are predisposed to gastric corpus-predominant inflammation after H. pylori infection. J Biomed Sci. 2017 Oct 30;24(1):82. doi: 10.1186/s12929-017-0389-x.
- Yang YJ, Wu CT, Ou HY, Lin CH, Cheng HC, Chang WL, Chen WY, Yang HB, Lu CC, Sheu BS. Ten days of levofloxacin-containing concomitant therapy can achieve effective Helicobacter pylori eradication in patients with type 2 diabetes. Ann Med. 2017 Sep;49(6):479-486. doi: 10.1080/07853890.2017.1294761. Epub 2017 Mar 7.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amoxicillin | Other / unclassified | 1000 mg | — |
| Comparator | Clarithromycin | Small molecule | 500 mg | — |
| Subject | Levofloxacin | Small molecule | 500 mg | — |
| Subject | Metronidazole | Small molecule | 500 mg | — |
| Background | Pantoprazole | Other / unclassified | 40 mg | — |